Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET
Company Participants
Jennifer Good - President and Chief Executive Officer
Lisa Delfini - Chief Financial Officer
Conference Call Participants
Annabel Samimy - Stifel
Serge Belanger - Needham and Company
Leland Gershell - Oppenheimer
William Wood - B. Riley Securities
Operator
Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company’s most recent annual report on Form 10-K which the company filed with the SEC this afternoon.
In addition, any forward-looking statement represent the company’s views only as of today and should not be relied upon as representing the company’s views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views change.
I would now like to turn the conference call over to Jennifer Good, Trevi’s President and CEO. Please go ahead.
Jennifer Good
Good afternoon. And thank you for joining our second quarter earnings call and business update. Joining me today on this call is Lisa Delfini, Trevi’s Chief Financial Officer. Lisa and I have some prepared remarks, then we will open it up for questions.
During the quarter, we continue to advance our clinical development plans’ for Haduvio and our chronic cough indications. Let me provide a brief update on each of our programs, beginning with our lead program in chronic cough and IPF. IPF is a serious end-of-life disease. Chronic cough and IPF impacts patients physically, psychologically, and socially, decreasing their quality of life. With no currently approved treatment options for chronic cough, there is an urgent need for new therapies. Chronic cough may also be a risk factor that plays a role in the progression of IPF. The constant lung injury, micro tears, and potential inflammation caused by persistent coughing may lead to worsening of disease and potential worsening of outcomes for patients.